Skip to main content
. Author manuscript; available in PMC: 2015 May 26.
Published in final edited form as: Cancer Epidemiol Biomarkers Prev. 2008 Aug;17(8):2087–2096. doi: 10.1158/1055-9965.EPI-08-0054

Figure 1.

Figure 1

Kaplan-Meier estimates for overall survival (A), disease-specific survival (B), and time-to-recurrence (C) by anti–HPV-16 VLP. Dashed line, anti–HPV-16 VLP–positive patients; solid line, anti–HPV-16 VLP antibody–negative patients; vertical tick marks, censored observations. Based on the log-rank test in unadjusted analyses, P = 0.09 for overall survival, P = 0.18 for disease-specific survival, and P = 0.13 for disease recurrence.